In contrast to an adverse prognostic value of SFRP1 or SFRP5 methylation in breast cancer, failure of SFRP2 methylation as a prognostic biomarker may be explained by redundant functions of these closely related SFRP molecules. The gene discussed is SFRP5; the disease is breast carcinoma.